The possible molecular mechanism is that intraperitoneally injected GnIH promoted adipogenesis and decreased lipolysis in the liver and WAT via inhibiting the AMPK signal pathway, resulting in hyperlipidemia and obesity (Figure 8). The gene discussed is PRKAB1; the disease is hyperlipidemia.